By comparing the efficacy between a fast-acting insulin (Actrapid®) and a liver-targeted insulin fused to ApoA1 (Ins–ApoA1), both co-administered with glucose, Solares et al. found that both exogenous insulins injected into AIP mice normalized heme biosynthesis, gluconeogenesis, and increased the number of mitochondria and the levels of circulating triglycerides, probably to promote the synthesis of high-energy molecules. The gene discussed is APOA1; the disease is autoimmune pancreatitis.